AbL Diagnostics SA - Asset Resilience Ratio
AbL Diagnostics SA (ABLD) has an Asset Resilience Ratio of 1.81% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of AbL Diagnostics SA to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how AbL Diagnostics SA's Asset Resilience Ratio has changed over time. See how leveraged is AbL Diagnostics SA's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down AbL Diagnostics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AbL Diagnostics SA market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €234.36K | 1.81% |
| Total Liquid Assets | €234.36K | 1.81% |
Asset Resilience Insights
- Limited Liquidity: AbL Diagnostics SA maintains only 1.81% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
AbL Diagnostics SA Industry Peers by Asset Resilience Ratio
Compare AbL Diagnostics SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
INVENTURUS KNOWLEDGE SO L
NSE:IKS |
Health Information Services | 0.39% |
|
Waystar Holding Corp. Common Stock
NASDAQ:WAY |
Health Information Services | 2.13% |
|
DocCheck AG
XETRA:AJ91 |
Health Information Services | 7.30% |
|
Pro Medicus Ltd
AU:PME |
Health Information Services | 54.64% |
|
Echoiq Ltd
AU:EIQ |
Health Information Services | 11.12% |
|
ARTRYA Ltd
AU:AYA |
Health Information Services | 32.70% |
|
Cogstate Ltd
AU:CGS |
Health Information Services | 54.90% |
|
Oneview Healthcare Plc
AU:ONE |
Health Information Services | 29.71% |
Annual Asset Resilience Ratio for AbL Diagnostics SA (2007–2025)
The table below shows the annual Asset Resilience Ratio data for AbL Diagnostics SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.81% | €234.36K ≈ $273.99K |
€12.95 Million ≈ $15.15 Million |
+0.78pp |
| 2024-12-31 | 1.03% | €121.08K ≈ $141.56K |
€11.81 Million ≈ $13.81 Million |
+1.02pp |
| 2023-12-31 | 0.00% | €184.00 ≈ $215.12 |
€14.90 Million ≈ $17.42 Million |
+0.00pp |
| 2022-12-31 | 0.00% | €184.00 ≈ $215.12 |
€15.41 Million ≈ $18.01 Million |
-99.60pp |
| 2021-12-31 | 99.60% | €2.70 Million ≈ $3.16 Million |
€2.71 Million ≈ $3.17 Million |
+0.40pp |
| 2020-12-31 | 99.20% | €2.36 Million ≈ $2.76 Million |
€2.38 Million ≈ $2.78 Million |
+2.52pp |
| 2019-12-31 | 96.68% | €6.97 Million ≈ $8.15 Million |
€7.21 Million ≈ $8.43 Million |
+3.13pp |
| 2018-12-31 | 93.55% | €7.25 Million ≈ $8.47 Million |
€7.75 Million ≈ $9.06 Million |
+69.72pp |
| 2017-12-31 | 23.84% | €1.79 Million ≈ $2.09 Million |
€7.51 Million ≈ $8.78 Million |
+0.71pp |
| 2016-12-31 | 23.13% | €1.60 Million ≈ $1.87 Million |
€6.92 Million ≈ $8.09 Million |
-7.73pp |
| 2015-12-31 | 30.86% | €2.29 Million ≈ $2.68 Million |
€7.42 Million ≈ $8.67 Million |
-31.72pp |
| 2014-12-31 | 62.58% | €4.11 Million ≈ $4.81 Million |
€6.57 Million ≈ $7.68 Million |
+11.67pp |
| 2013-12-31 | 50.91% | €3.01 Million ≈ $3.52 Million |
€5.91 Million ≈ $6.90 Million |
+23.53pp |
| 2012-12-31 | 27.38% | €1.45 Million ≈ $1.70 Million |
€5.29 Million ≈ $6.19 Million |
-63.26pp |
| 2008-12-31 | 90.65% | €4.55 Million ≈ $5.32 Million |
€5.02 Million ≈ $5.87 Million |
-1.27pp |
| 2007-12-31 | 91.92% | €4.50 Million ≈ $5.26 Million |
€4.90 Million ≈ $5.72 Million |
-- |
About AbL Diagnostics SA
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more